Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting In Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (Alliance A221602)
- Citation:
- J Clin Oncol vol 40 (suppl 16) abstr 12107
- Meeting Instance:
- ASCO 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3718
- Program:
- CCP
- Primary Committee:
- Symptom Inter
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Grants:
- UG1CA189823
- Corr. Author:
- Authors:
- Rudolph M Navari Jennifer Le-Rademacher Fabrice Smieliauskas Kathryn J. Ruddy Thomas J. Saphner Heshan Liu Beth Harlos Adedayo Onitilo Karthik Giridhar Preet Paul Singh Pavan Reddy Flavio Kruter George Raptis Charles L. Loprinzi
- Networks:
- AURORA, HEARTLAND, KS055, LAPS-AL002, LAPS-MN026, MD020, MI020, NORTHWELL, WINCORP
- Study
- Alliance-A221602
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: